2024
Dupilumab-associated head and neck dermatitis shows a pronounced type 22 immune signature mediated by oligoclonally expanded T cells
Bangert C, Alkon N, Chennareddy S, Arnoldner T, Levine J, Pilz M, Medjimorec M, Ruggiero J, Cohenour E, Jonak C, Damsky W, Griss J, Brunner P. Dupilumab-associated head and neck dermatitis shows a pronounced type 22 immune signature mediated by oligoclonally expanded T cells. Nature Communications 2024, 15: 2839. PMID: 38565563, PMCID: PMC10987549, DOI: 10.1038/s41467-024-46540-0.Peer-Reviewed Original ResearchConceptsHead and neck dermatitisAtopic dermatitisNeck dermatitisT cellsHealthy control skinType 2 inflammationDupilumab treatmentImmune signaturesReceptor upregulationActivation markersClinical efficacyPunch biopsyHistopathological featuresDe novo appearanceIL-22Single-cell RNA sequencingDrug effectsDupilumabSide effectsControl skinDermatitisKeratinocyte activationUntreated ADTreatmentRNA sequencing
2023
Targeting interleukin (IL)-4/IL-13 in immune checkpoint inhibitor-induced bullous pemphigoid: a cautionary note on the beneficial effect of T helper 2 immunity in melanoma and immunotherapy: reply from the authors
Shipman W, Singh K, Cohen J, Leventhal J, Damsky W, Tomayko M. Targeting interleukin (IL)-4/IL-13 in immune checkpoint inhibitor-induced bullous pemphigoid: a cautionary note on the beneficial effect of T helper 2 immunity in melanoma and immunotherapy: reply from the authors. British Journal Of Dermatology 2023, 190: 138-138. PMID: 37947404, DOI: 10.1093/bjd/ljad342.Peer-Reviewed Original ResearchImmune checkpoint inhibitor-induced bullous pemphigoid is characterized by interleukin (IL)-4 and IL-13 expression and responds to dupilumab treatment
Shipman W, Singh K, Cohen J, Leventhal J, Damsky W, Tomayko M. Immune checkpoint inhibitor-induced bullous pemphigoid is characterized by interleukin (IL)-4 and IL-13 expression and responds to dupilumab treatment. British Journal Of Dermatology 2023, 189: 339-341. PMID: 37140007, PMCID: PMC10947518, DOI: 10.1093/bjd/ljad149.Peer-Reviewed Original ResearchMeSH KeywordsAntibodies, Monoclonal, HumanizedHumansImmune Checkpoint InhibitorsInterleukin-13Pemphigoid, BullousConceptsIL-13 expressionBullous pemphigoidImmune-related adverse eventsComplete disease clearancePromising new therapyNovel therapeutic approachesDisease clearanceAdverse eventsTumor immunityTherapeutic approachesNew therapiesConventional treatmentPemphigoidInterleukinTreatmentPatientsExpressionTherapyImmunityClearanceBaseline skin cytokine profiles determined by RNA in situ hybridization correlate with response to dupilumab in patients with eczematous dermatitis
Singh K, Valido K, Swallow M, Okifo K, Wang A, Cohen J, Damsky W. Baseline skin cytokine profiles determined by RNA in situ hybridization correlate with response to dupilumab in patients with eczematous dermatitis. Journal Of The American Academy Of Dermatology 2023, 88: 1094-1100. PMID: 36780951, DOI: 10.1016/j.jaad.2022.12.052.Peer-Reviewed Original ResearchConceptsEczematous dermatitisHistologic featuresTreatment selectionType 1Type 3 inflammationInflammatory skin diseaseCertain histologic featuresSitu hybridization correlatesClinical responseNonresponder groupCytokine profileCytokine stainingAtopic dermatitisCytokine RNAEczematous disordersSitu hybridizationDupilumabIL13 expressionSkin diseasesType 2PatientsDermatitisNonrespondersMolecular heterogeneityImproved response